Biostatistics - Summer 2026 Intern jobs in United States
info-icon
This job has closed.
company-logo

Sanofi · 4 months ago

Biostatistics - Summer 2026 Intern

Sanofi is an innovative global healthcare company committed to improving people’s lives. They are seeking a Summer 2026 Intern for their Biostatistics team, where the intern will apply machine learning techniques to optimize dosing strategies in clinical development.

Health CareLife SciencePharmaceuticalTherapeutics
badNo H1Bnote

Responsibilities

Design and implement deep reinforcement learning models for dose optimization in clinical trial settings
Conduct simulation studies to evaluate model performance under various clinical scenarios
Compare DRL-based approaches with traditional dose-finding methods
Collaborate with statisticians and clinical scientists to ensure clinical relevance and interpretability
Document methodology, results, and insights for internal presentations and potential publications

Qualification

Deep reinforcement learningMachine learningStatistical modelingPyTorchPython-based data science toolsCommunicationCollaboration skills

Required

Current PhD student in Statistics, Biostatistics, Computer Science, Applied Mathematics, or a related field at an accredited college or university
Experience and foundation in machine learning, with specific experience in deep learning and/or reinforcement learning
Hands-on experience with PyTorch, Gymnasium (or similar RL environments), and Python-based data science tools
Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op/internship
Must be authorized to work in the US for the full duration of the co-op/internship

Preferred

Familiarity with clinical trial design and statistical modeling is a plus
Excellent communication and collaboration skills

Benefits

Enjoy a thoughtful, well-crafted rewards package that recognizes your contribution and amplifies your impact.

Company

Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.

Funding

Current Stage
Public Company
Total Funding
$6.97B
Key Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B

Leadership Team

leader-logo
Paul Hudson
Chief Executive Officer
linkedin
leader-logo
Francois-Xavier Roger
Chief Financial Officer
linkedin
Company data provided by crunchbase